FTT PET/CT in Metastatic Prostate Cancer

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Feb 8, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of imaging called FTT PET/CT scans to help doctors understand how well a new treatment for metastatic prostate cancer is working. Up to 30 men who have been diagnosed with prostate cancer that has spread to other parts of the body may be eligible to participate. To qualify, participants need to be at least 18 years old, have been diagnosed with prostate cancer confirmed by a tissue sample, and have evidence of cancer spread shown on standard imaging tests. They should also be considering a new treatment, which could include therapies that target the cancer's growth.

Participants in the study will have up to two FTT PET/CT scans. The first scan will take place before they start any new treatment, and if they choose, they can have a second scan about 1 to 3 weeks after starting the treatment. These scans will help researchers see how the treatment is affecting the cancer. It's important to know that participants will need to give their written consent and understand that this study involves experimental procedures. Overall, this trial aims to improve treatment strategies for men with metastatic prostate cancer by providing valuable information about the effectiveness of new therapies.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants will be ≥ 18 years of age
• • 2. Histologically proven prostate carcinoma
• • 3. Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound)
• • 4. Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.
• • 5. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Exclusion Criteria:
• • 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• • 2. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study